Application Note: Balancing the dangers of sepsis and antimicrobial resistance
27 August 2021

In recent years, awareness campaigns and policy decisions have contributed to a “better safe than sorry” approach to treating sepsis. This means patients may receive unnecessary antibiotics, a trend that can act as a contributing factor to the development of antimicrobial resistance (AMR). 

In this application note, Thermo Fisher Scientific outlines the complex etiology of sepsis and the importance of stewardship, biomarkers, and advanced diagnostics in its treatment.